Edition:
United Kingdom

Anthem Inc (ANTM.N)

ANTM.N on New York Stock Exchange

277.86USD
20 Nov 2018
Change (% chg)

$-3.93 (-1.39%)
Prev Close
$281.79
Open
$280.00
Day's High
$282.12
Day's Low
$276.59
Volume
201,621
Avg. Vol
320,694
52-wk High
$290.77
52-wk Low
$215.58

Select another date:

Wed, Oct 31 2018

Photo

Anthem predicts better 2019 than Wall Street forecast, shares rise

Anthem Inc on Wednesday said its own expectations for 2019 earnings are ahead of current Wall Street estimates and the health insurer also raised its 2018 profit forecast, and its shares rose as much as 5 percent.

UPDATE 3-Anthem predicts better 2019 than Wall Street forecast, shares rise

Oct 31 Anthem Inc on Wednesday said its own expectations for 2019 earnings are ahead of current Wall Street estimates and the health insurer also raised its 2018 profit forecast, and its shares rose as much as 5 percent.

CORRECTED-UPDATE 1-Anthem quarterly profit beats estimates, raises 2018 forecast

Oct 31 Anthem Inc reported quarterly profit that topped analysts' estimates on Wednesday on lower medical costs and the No.2 U.S. health insurer raised its full-year adjusted earnings forecast.

Takeda hikes annual profit forecast by a third after second-quarter profit jump

TOKYO Japan's Takeda Pharmaceutical Co Ltd on Wednesday boosted its annual operating profit outlook by a third after second-quarter earnings surged on strong global sales of its drugs for bowel disease and multiple myeloma.

UPDATE 2-Takeda hikes annual profit forecast by a third after Q2 profit jump

* Boosted by strong sales of bowel disease, multiple myeloma drugs (Adds executive comments from news conference)

Anthem reports 28.5 pct rise in quarterly profit

Oct 31 Anthem Inc reported a 28.5 percent rise in quarterly profit on Wednesday, as the U.S. health insurer reined in medical costs.

Takeda hikes annual profit outlook by a third after second quarter profit jump

TOKYO Japan's Takeda Pharmaceutical Co Ltd boosted its annual operating profit outlook by a third after second-quarter earnings surged on strong global sales of its drugs for bowel disease and multiple myeloma.

Takeda's raises full-year outlook after Q2 profit rise

TOKYO, Oct 31 Takeda Pharmaceutical Co Ltd on Wednesday raised its annual operating profit outlook to 268.9 billion yen.

Takeda proposes sale of Shire drug to gain European approval

Takeda Pharmaceutical Co Ltd has proposed to European regulators it could sell a Shire treatment in development due to concerns of overlap in inflammatory bowel disease treatments and its own drug Entyvio as it seeks clearance for the two companies' merger.

Takeda proposes sale of Shire drug to gain European approval

Takeda Pharmaceutical Co Ltd has proposed to European regulators it could sell a Shire treatment in development due to concerns of overlap in inflammatory bowel disease treatments and its own drug Entyvio as it seeks clearance for the two companies' merger.

Select another date: